Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial.
Lau G, Sangro B, Cheng AL, Kudo M, Kelley RK, Tak WY, Gasbarrini A, Reig M, Lim HY, Tougeron D, De Toni EN, Tam VC, Mody K, Gong J, Crysler OV, Sukeepaisarnjaroen W, Lipatov O, Morimoto M, Archambeaud I, Burgio V, Phuong LTT, Chao Y, Peron JM, Berres ML, Ko YJ, Ran D, Makowsky M, Negro A, Abou-Alfa GK. Lau G, et al. Among authors: berres ml. Hepatology. 2025 May 16. doi: 10.1097/HEP.0000000000001385. Online ahead of print. Hepatology. 2025. PMID: 40384092
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Kelley RK, et al. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16. Lancet. 2023. PMID: 37075781 Free article. Clinical Trial.
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab.
Gairing SJ, Mildenberger P, Gile J, Artusa F, Scheiner B, Leyh C, Lieb S, Sinner F, Jörg V, Fruendt T, Himmelsbach V, Abedin N, Sahin C, Böttcher K, Schuhbaur J, Labuhn S, Korolewicz J, Fulgenzi CAM, D'Alessio A, Zanuso V, Hucke F, Röhlen N, Ben Khaled N, Ramadori E, Müller L, Weinmann A, Kloeckner R, Galle PR, Tran NH, Venkatesh SK, Teufel A, Ebert M, De Toni EN, Waldschmidt DT, Marquardt JU, Bettinger D, Peck-Radosavljevic M, Geier A, Reiter FP, Rimassa L, Pinato DJ, Roderburg C, Ettrich T, Bitzer M, Scheble V, Ehmer U, Berres ML, Finkelmeier F, Gonzalez-Carmona MA, von Felden J, Schulze K, Venerito M, van Bömmel F, Jochheim LS, Pinter M, Mohr R, Ilyas SI, Schmidtmann I, Foerster F. Gairing SJ, et al. Among authors: berres ml. JHEP Rep. 2024 Dec 5;7(3):101295. doi: 10.1016/j.jhepr.2024.101295. eCollection 2025 Mar. JHEP Rep. 2024. PMID: 40059970 Free PMC article.
Survival after combined resection and ablation is not inferior to that after resection alone, in patients with four or more colorectal liver metastases.
Amygdalos I, Hitpass L, Schmidt F, Josephs G, Bednarsch J, Berres ML, Lüdde T, Olde Damink SWM, Ulmer TF, Neumann UP, Bruners P, Lang SA. Amygdalos I, et al. Among authors: berres ml. Langenbecks Arch Surg. 2023 Aug 29;408(1):343. doi: 10.1007/s00423-023-03082-1. Langenbecks Arch Surg. 2023. PMID: 37642753 Free PMC article.
Splenic hypertrophy predicts liver-specific complications in patients undergoing major liver resection for colorectal liver metastases, after preoperative chemotherapy.
Josephs G, Hitpass L, Truhn D, Meister F, Berres ML, Luedde T, Jonigk D, Olde Damink SWM, Lang SA, Vondran F, Amygdalos I. Josephs G, et al. Among authors: berres ml. Hepatobiliary Surg Nutr. 2025 Jun 1;14(3):411-422. doi: 10.21037/hbsn-24-121. Epub 2024 Sep 18. Hepatobiliary Surg Nutr. 2025. PMID: 40529910 Free PMC article.
Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study.
Möhring C, Berger M, Sadeghlar F, Zhou X, Zhou T, Monin MB, Shmanko K, Welland S, Sinner F, Schwacha-Eipper B, Bauer U, Roderburg C, Pirozzi A, Ben Khaled N, Schrammen P, Balcar L, Pinter M, Ettrich TJ, Saborowski A, Berres ML, De Toni EN, Lüdde T, Rimassa L, Ehmer U, Venerito M, Radu IP, Schmidt-Wolf IGH, Weinmann A, Vogel A, Schmid M, Kalff JC, Strassburg CP, Gonzalez-Carmona MA. Möhring C, et al. Among authors: berres ml. Cancers (Basel). 2025 Mar 13;17(6):972. doi: 10.3390/cancers17060972. Cancers (Basel). 2025. PMID: 40149306 Free PMC article.
75 results